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Abstract Ϯϳ 
Despite recent advances in diagnostic and therapeutic advances in antifungal Ϯϴ 
research, aspergillosis still remains a leading cause of morbidity and mortality. One Ϯϵ 
strategy to address this problem is to enhance the activity spectrum of known ϯϬ 
antifungals, and we now report the first successful application of Candida antarctica ϯϭ 
lipase (CAL) for the preparation of optically enriched fluconazole analogs. Anti-ϯϮ 
Aspergillus activity was observed for an optically enriched derivative, (-)-S-2-(2',4'-ϯϯ 
difluorophenyl)-1-hexyl-amino-3-(1''',2''',4''') triazol-1'''-yl-propan-2-ol, which exhibits ϯϰ 
MIC values of 15.6 µg/mL and 7.8 µg/disc in microbroth dilution and disc diffusion ϯϱ 
assays, respectively. This compound is tolerated by mammalian erythrocytes and ϯϲ 
cell lines (A549 and U87) at concentrations of up to 1000 µg/mL. When incorporated ϯϳ 
into dextran nanoparticles, the novel, optically enriched fluconazole analog exhibited ϯϴ 
improved antifungal activity against Aspergillus fumigatus (MIC = 1.63 µg/mL). ϯϵ 
These results not only demonstrate the ability of biocatalytic approaches to yield ϰϬ 
novel, optically enriched fluconazole derivatives but also suggest that ϰϭ 
enantiomerically pure fluconazole derivatives, and their nanotised counterparts, ϰϮ 
exhibiting anti-Aspergillus activity may have reduced toxicity.  ϰϯ 
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Aspergillosis remains a significant threat to public health, and, in spite of ϰϰ 
continuous efforts to improve timely diagnosis and clinical therapies, mortality ϰϱ 
caused by this disease remains unacceptably high [1, 2]. Current therapeutic ϰϲ 
options for treating Aspergillus-induced disorders include antifungal agents ϰϳ 
such as polyenes, azoles and echinocandins [3, 4]. Thus the discovery of new ϰϴ 
antifungal compounds remains important given the need to address the ϰϵ 
development of drug resistance in pathogenic fungi [5-7]. One approach to ϱϬ 
accomplishing this goal is to prepare new derivatives of existing drugs with ϱϭ 
broad spectrum activity and enhanced pharmacokinetic properties. As part of ϱϮ 
our on-going efforts to use lipases [8-12], which catalyze reactions with high ϱϯ 
degree of chemo-, regio- and stereoselectivity in organic synthesis, we ϱϰ 
became interested in preparing new antifungals using biocatalysis. ϱϱ 
 Fluconazole, introduced in 1990, is a bis-triazole antifungal drug which ϱϲ 
possesses interesting pharmacokinetic properties, such as low plasma binding ϱϳ 
affinity, good water solubility, low first pass metabolism, high oral ϱϴ 
bioavailability and a long half-life, all of which should make it a drug of choice ϱϵ 
for treating fungal infections [13, 14]. On the other hand, fluconazole has been ϲϬ 
reported to exhibit only limited activity against Aspergillus infections [15], ϲϭ 
which has led to many reports concerning the synthesis of various types of ϲϮ 
fluconazole derivatives and their chiral separation/resolution into constituent ϲϯ 
enantiomers [16-19]. We now report the use of Candida antarctica lipase ϲϰ 
(CAL-B) in catalysing the addition of amines to an achiral epoxide to yield ϲϱ 
optically enriched fluconazole analogues in which one of the triazole rings is ϲϲ 
replaced by n-alkylamino and cycloalkylamino substituents. To the best of our ϲϳ 
knowledge, the work reported herein is the first direct synthesis of optically ϲϴ 
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enriched fluconazole analogues using biocatalytic methods. In vitro assays ϲϵ 
show that the optically enriched analogues exhibit more potent antifungal ϳϬ 
activity than the corresponding racemic mixtures. Interestingly, this bioactivity ϳϭ 
can be enhanced by their encapsulation in dextran-based nanoparticles [20]. ϳϮ 
 ϳϯ 
Results ϳϰ 
Synthesis of fluconazole analogues. A series of linear and cyclic alkylamines ϳϱ 
was screened for reaction with the epoxide ring of (±)-1-[2-(2, 4-difluorophenyl)-ϳϲ 
oxiranylmethyl]-1H-[1,2,4]-triazole (1, Figure 1) in a number of different organic ϳϳ 
solvents. Three different immobilized lipases were also evaluated for their ability to ϳϴ 
catalyze this reaction: Candida rugosa lipase (CRL), porcine pancreatic lipase (PPL) ϳϵ 
and CAL-B. Although the ring-opening reactions catalysed by CRL and PPL were of ϴϬ 
no practical utility, when the reaction was performed in the presence of CAL-B in ϴϭ 
tetrahydrofuran (THF) as solvent, the desired products (3a-j, 5a and 5b) were ϴϮ 
obtained with good yields in optically enriched forms (Figure 1, and Tables S1 and ϴϯ 
S2 in Supporting Information). Very importantly, all of the twelve novel fluconazole ϴϰ 
analogues formed in the lipase-catalyzed reactions were optically active showing ϴϱ 
that aminolysis of the racemic starting epoxide (±)-1 had proceeded in an ϴϲ 
enantioselective fashion (Table S1). These twelve compounds could also be ϴϳ 
prepared in racemic form, as viscous oils in 75-80 % yields, by direct reaction of the ϴϴ 
alkylamines with the racemic epoxide precursor (±)-1 in THF at 55 oC. The time ϴϵ 
taken for complete consumption of aliphatic amines 2a-j, 4a and 4b in the CAL-B ϵϬ 
catalyzed reaction varied between 18h and 28h, which was considerably shorter ϵϭ 
than the 48-56 h required for the chemical addition of the amines (Table S2 in ϵϮ 
Supporting Information). The structures of all twelve fluconazole analogues were ϵϯ 
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unambiguously established on the basis of spectroscopic data (IR, 1H- and 13C NMR, ϵϰ 
and mass spectra), and by comparison to literature data for known compounds 3b, ϵϱ 
3c, 5a and 5b [21, 22].  ϵϲ 
 Although the enantiomeric enrichment of the fluconazole analogues prepared ϵϳ 
by lipase-catalyzed addition was not established, we were able to assign the ϵϴ 
absolute configuration of the major enantiomer using the optical activity of the ϵϵ 
unreacted epoxide isolated from the reaction mixture. These samples rotated ϭϬϬ 
polarized light in a positive (+) direction, meaning that the recovered, unreacted ϭϬϭ 
epoxide was enriched in the enantiomer for which the stereogenic centre has the (S) ϭϬϮ 
configuration (Table S1 in Supporting Information) [23]. CAL-B therefore ϭϬϯ 
preferentially employs (-)-R-1 in the aminolysis reaction and, assuming a standard ϭϬϰ 
SN2 mechanism for reaction of the amine with the epoxide, we can deduce that the ϭϬϱ 
fluconazole analogues must be enriched in the (-)-S-enantiomer (Figure 1).  ϭϬϲ 
 ϭϬϳ 
Antifungal activities of the fluconazole analogs Pathogenic Aspergillus ϭϬϴ 
strains (Aspergillus fumigatus ITCC 6604, Aspergillus flavus ITCC 5192, and ϭϬϵ 
Aspergillus niger ITCC 0004) were used to determine the in vitro antifungal efficacy ϭϭϬ 
of the fluconazole analogues, in both their optically enriched and racemic forms. ϭϭϭ 
These experiments used standard microbroth dilution (MDA), disc diffusion (DDA) ϭϭϮ 
and spore germination inhibition (PSGI) assays [24, 25]. We note that the MDA ϭϭϯ 
assay is based on the same basic principle as that used in the CLSI micro-dilution ϭϭϰ 
protocol. The only difference between the two assays is that CLSI uses RPMI ϭϭϱ 
medium to prepare diluted drug solutions rather than the Sabouraud dextrose broth ϭϭϲ 
(a medium used to culture Aspergillii in the laboratory) used by us to determine the ϭϭϳ 
MIC of the fluconazole derivatives. As recommended in CLSI protocols, we carefully ϭϭϴ 
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monitored MDA parameters with respect to preparation of the test compounds, ϭϭϵ 
medium preparation, temperature, inoculum size, incubation time, minimum ϭϮϬ 
inhibitory concentration (MIC)/endpoint determination, data recording and ϭϮϭ 
interpretation of results to ensure the validity and quality of our results. On this point, ϭϮϮ 
we note that a previous study from our laboratory [26] showed that results with RPMI ϭϮϯ 
1640 or RPMI 1640 containing glucose were not different from those obtained by ϭϮϰ 
using Sabouraud dextrose broth.  ϭϮϱ 
On the basis of their MIC values, all the compounds exhibited moderate to ϭϮϲ 
good anti-Aspergillus activities, with the analogue (-)-S-3d being more potent than ϭϮϳ 
the commercially available fluconazole (Table 1). We also observed that optically ϭϮϴ 
enriched mixtures of (-)-S-3a, (-)-S-3c, (-)-S-3d, (-)-S-3e and (-)-S-5b were more ϭϮϵ 
active than the corresponding racemates. These data also confirm that introducing a ϭϯϬ 
linear aliphatic alkyl side chain is important for imparting antifungal activity, as ϭϯϭ 
reported previously [23, 24]. On the other hand, when additional, “distal” N-ϭϯϮ 
substituted alkyl groups were present, as in compounds (-)-S-3g and (-)-S-3h, ϭϯϯ 
antifungal activity was completely lost (Table 1). Compounds 3j and 5a exhibited no ϭϯϰ 
biological activity in microbroth dilution assays and were not studied further. Our ϭϯϱ 
work also shows that the length of the alkyl side chain is an important factor in ϭϯϲ 
determining activity, i.e. the compound (-)-S-3d, containing an n-hexyl moiety, has ϭϯϳ 
higher activity than (-)-S-3a, (-)-S-3b and (-)-S-3c, which contain ethyl, n-propyl and ϭϯϴ 
n-butyl groups, respectively (Table 1). Decreasing the linker chain length also led to ϭϯϵ 
higher activity. Optically enriched (-)-S-3d was the most potent compound against ϭϰϬ 
Aspergillus fumigatus (Table 1) and was therefore used to examine how ϭϰϭ 
encapsulation in dextran nanoparticles might impact anti-fungal activity. ϭϰϮ 
 ϭϰϯ 
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Characterization of (-)-S-3d release from O-alkylated dextran ϭϰϰ 
nanoparticles. Dextran nanoparticle-based drug delivery systems are ϭϰϱ 
biocompatible, biodegradable, possess low immunogenicity [20], and can be used ϭϰϲ 
for controlled release of pharmacologically active substances [27]. We therefore ϭϰϳ 
encapsulated optically enriched (-)-S-3d into three types of dextran nanoparticles, ϭϰϴ 
derivatized with O-hexadecyl, O-decyl and O-heptyl chains to ensure amphiphilicity, ϭϰϵ 
and examined their effect on anti-Aspergillus activity. After trapping (-)-S-3d within ϭϱϬ 
each of the nanoparticles by self-assembly (encapsulation efficiencies for the O-ϭϱϭ 
hexadecyl, O-decyl and O-heptyl nanoparticles were 50 ± 4 %, 22 ± 2 % and 30 ± 2 ϭϱϮ 
%), the resulting particle size distributions were determined using dynamic light ϭϱϯ 
scattering (DSL). These measurements showed that the sizes of the O-hexadecyl-, ϭϱϰ 
O-decyl- and O-heptyl- derivatized nanoparticles were 140 ± 16 nm, 187 ± 13.16 nm ϭϱϱ 
and 183 ± 14.73 nm, respectively, and that all of the samples had a low ϭϱϲ 
polydispersity index (< 0.3) (Supporting Information). Examination of the rate at ϭϱϳ 
which the fluconazole analogue (-)-(S)-3d was released from each of the three types ϭϱϴ 
of nanoparticles, showed an initial burst for the O-hexadecyl- and O-decyl-ϭϱϵ 
derivatized nanoparticles (Figure 2).  ϭϲϬ 
 ϭϲϭ 
Anti-Aspergillus activity and cytotoxicity of (-)-S-3d encapsulated in O-ϭϲϮ 
alkylated dextran nanoparticles. We next examined the effect of nanoparticle ϭϲϯ 
encapsulation on the activity of (-)-S-3d against Aspergillus fumigatus using a ϭϲϰ 
microbroth dilution assay (Figure 3). After 48 h of incubation (approximately 80 % ϭϲϱ 
release), (-)-S-3d encapsulated in O-decyl-derivatized nanoparticles inhibited the ϭϲϲ 
growth of Aspergillus fumigatus at an effective concentration of 3.16 µg/mL. Perhaps ϭϲϳ 
more importantly, when the optically enriched fluconazole analogue was ϭϲϴ 
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encapsulated in O-hexadecyl nanoparticles, complete inhibition of Aspergillus ϭϲϵ 
fumigatus growth was achieved at an effective concentration of 1.63 µg/mL (41.3 % ϭϳϬ 
release at an initial concentration of 3.95 µg/mL). In addition, nanoparticle-ϭϳϭ 
encapsulated (-)-S-3d exhibits activity at a lower concentration when compared to ϭϳϮ 
both fluconazole and free (-)-S-3d. Although we believe that this effect is associated ϭϳϯ 
with sustained release of the compound over time, it is also possible that drug ϭϳϰ 
uptake is more efficient because the drug in its encapsulated form is more efficiently ϭϳϱ 
captured by the cells. The general importance of this observation is also evident from ϭϳϲ 
the fact that the MIC of amphotericin B was decreased from 1.95 µg/mL to 0.97 ϭϳϳ 
µg/mL when the drug was encapsulated in O-heptyl nanoparticles. ϭϳϴ 
 The cytotoxicity of (-)-S-3d and amphotericin B when encapsulated in ϭϳϵ 
derivatized nanoparticles was also evaluated using haemolysis and MTT-based ϭϴϬ 
assays (Figure 4). Perhaps unsurprisingly, given that erythrocytes and cell lines ϭϴϭ 
treated with empty dextran nanoparticles (> 90 % cell viability at concentrations of 2 ϭϴϮ 
mg/mL) remained completely viable up to 1 mg/mL, the encapsulated, optically ϭϴϯ 
enriched fluconazole analogue (-)-S-3d exhibited similar cytotoxicity to that of the ϭϴϰ 
free compound. Thus, essentially no toxicity to two human cell lines (Figures 4b and ϭϴϱ 
4c) was seen when the compound was present at concentrations similar to the MIC ϭϴϲ 
values observed for its anti-fungal activity. The optically enriched fluconazole ϭϴϳ 
analogue (-)-S-3d was also considerably less cytotoxic than free amphotericin B in ϭϴϴ 
all assays (Figure 4). It is therefore interesting to note that encapsulating ϭϴϵ 
amphotericin B into O-hexadecyl derivatized nanoparticles lowered the cytotoxicity of ϭϵϬ 
this antifungal agent in both the hemolysis and MTT-based assays. Nevertheless, ϭϵϭ 
cell viability was reduced for amphotericin B-containing nanoparticles relative to ϭϵϮ 
derivatized nanoparticles containing fluconazole analogue (-)-S-3d. ϭϵϯ 
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Conclusions ϭϵϰ 
Reacting alkylamines with a racemic epoxide precursor (Figure 1) in the ϭϵϱ 
presence of immobilized lipase CAL-B in THF provides a simple approach for ϭϵϲ 
the preparation of optically enriched fluconazole analogs, which appear to ϭϵϳ 
exhibit better antifungal activity against Aspergillus than fluconazole. Although ϭϵϴ 
the extent to which the enzyme catalyzes the coupling reaction in an ϭϵϵ 
enantioselective manner remains to be determined, we have been able to ϮϬϬ 
assign the (S)-configuration to the stereogenic centre of the enantiomer that ϮϬϭ 
exhibits biological activity, assuming that (i) the aminolysis reaction proceeds ϮϬϮ 
with its usual chemical mechanism, and (ii) only one enantiomer has antifungal ϮϬϯ 
activity. Given the difficulty of single-step chemical strategies for the ϮϬϰ 
preparation of chiral fluconazoles in optically enriched form, we anticipate that ϮϬϱ 
the enzymatic methodology reported herein will have significant impact in this ϮϬϲ 
approach to obtaining novel variants of existing antifungal drugs. ϮϬϳ 
 The most active analogue prepared in this study, (-)-S-3d, is more ϮϬϴ 
potent against Aspergillus fumigatus than fluconazole, having MIC values of 8-ϮϬϵ 
16 µg/mL in a series of in vitro assays. Perhaps more importantly for drug ϮϭϬ 
discovery, the anti-Aspergillus potency of this compound is enhanced (MIC Ϯϭϭ 
1.6-4.0 µg/mL) by encapsulation in derivatized nanoparticles, with minimal in ϮϭϮ 
vitro cytotoxic effects at concentrations of up to 2 mg/mL against human Ϯϭϯ 
erythrocytes and cell lines of human origin. Ϯϭϰ 
 Ϯϭϱ 
Materials and Methods Ϯϭϲ 
General procedure for the CAL-B catalysed synthesis of optically Ϯϭϳ 
enriched fluconazole analogues. CAL-B immobilized on accurel beads (300 Ϯϭϴ 
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mg) was added to a solution of the epoxide (±)-1 (5.0 mmol) and the appropriate Ϯϭϵ 
amine (2a-j, 4a or 4b, 2.5 mmol) dissolved in THF, and the mixture incubated at 55 ϮϮϬ 
°C. The extent of the reaction was monitored by TLC and the enzyme was removed ϮϮϭ 
by filtration when the amine was consumed. After removal of THF at reduced ϮϮϮ 
pressure, the residue was subjected to column chromatography using chloroform/ ϮϮϯ 
methanol as eluent to afford optically enriched samples of pure fluconazole ϮϮϰ 
analogues (-)-S-3a-3j, (-)-S-5a or (-)-S-5b and the unreacted epoxide (+)-S-1. ϮϮϱ 
 ϮϮϲ 
(-)-S-2-(2',4'-Difluorophenyl)-1-hexylamino-3-(1''',2''',4''')triazol-1'''-yl-prop-ϮϮϳ 
an-2-ol (3d) was obtained as a viscous oil in 80% yield. [α] D20 -20.3 (c 0.01, ϮϮϴ 
CHCl3); IR spectrum (film) µmax: 3315 (OH and NH), 2979, 1620, 1508, 1415, 1267, ϮϮϵ 
1145, 960 cm-1. 1H NMR (400 MHz, CDCl3): δ 0.83 (3H, t, J = 7.63 Hz), 1.17-1.33 ϮϯϬ 
(8H, m), 2.43 (2H, t, J = 6.87 Hz), 2.81 (1H, d, J = 12.97 Hz), 3.12 (1H, d, J = 12.21 Ϯϯϭ 
Hz), 4.49 (1H, d, J = 14.50 Hz), 4.58 (1H, d, J = 13.73 Hz), 6.74-6.82 (2H, m), 7.50-ϮϯϮ 
7.55 (1H, m), 7.77 (1H, s) and 8.10 (1H, s). 13C NMR (100 MHz, CDCl3): δ 13.92, Ϯϯϯ 
22.46, 26.55, 29.83, 31.49, 50.00, 54.14 (d, JCF= 3.83 Hz), 55.98 (d, JCF= 4.79 Hz), Ϯϯϰ 
72.96 (d, JCF= 5.75 Hz), 104.12 (d, JCF=26.84 Hz), 111.38 (d, JCF= 20.61 Hz), 125.05 Ϯϯϱ 
(d, JCF = 13.42 Hz), 129.79 (d, JCF = 6.71 Hz), 144.60, 151.09, 158.92 (d, JCF = Ϯϯϲ 
237.78 Hz) and 162.29 (d, JCF = 249.20 Hz). HRMS: m/z 339.1991 ([M+H]+, Ϯϯϳ 
C17H25F2N4O calcd. 339.1969). Ϯϯϴ 
 Ϯϯϵ 
Microbroth dilution assay Various concentrations of different derivatives in the ϮϰϬ 
range of 0.24-1000.0 µg/mL were prepared in 96 well culture plates (Nunc, Roskilde, Ϯϰϭ 
Denmark) by serial dilution in Sabouraud dextrose broth. Wells were inoculated with ϮϰϮ 
1 x 106 spores (conidia) of Aspergillus in 10 µL of spore suspension. Negative Ϯϰϯ 
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controls were solvent in medium and spores only, with amphotericin B and Ϯϰϰ 
fluconazole being used as positive controls. Plates were incubated at 37 ºC using a Ϯϰϱ 
BOD incubator (Calton, NSW, India) and examined macroscopically after 48 h for the Ϯϰϲ 
growth of Aspergillus mycelia. The activity of the analogues was defined as positive Ϯϰϳ 
if the medium appeared clear without any growth of Aspergillus mycelia, and the Ϯϰϴ 
minimum concentration of compounds inhibiting growth was reported as MIC (Table Ϯϰϵ 
1). ϮϱϬ 
 Ϯϱϭ 
Disc diffusion assay Autoclaved Sabouraud dextrose agar (SDA) was poured into ϮϱϮ 
radiation-sterilized petri dishes (10.0 cm diameter). A suspension of conidia of Ϯϱϯ 
Aspergillus was prepared and overlaid on the agar plates. Different concentrations of Ϯϱϰ 
the fluconazole analogues were impregnated on 5.0 mm diameter sterilized discs Ϯϱϱ 
(Whatman No. 1) and placed on the agar. Control discs containing solvent, Ϯϱϲ 
amphotericin B or fluconazole were also included in the assay. Plates were Ϯϱϳ 
incubated at 37 ºC and the zone of inhibition determined after 72 h. MICs reported Ϯϱϴ 
for this assay  (Table 1) correspond to fluconazole analogue concentrations giving a Ϯϱϵ 
zone of inhibition of at least 6.0 mm diameter from the centre of the plate. ϮϲϬ 
 Ϯϲϭ 
Percent spore germination inhibition assay Serial dilutions, ranging from 0.24-ϮϲϮ 
1000.0 µg/mL, of each fluconazole analogue dissolved in Sabouraud dextrose broth Ϯϲϯ 
were placed in radiation-sterilized petri dishes (10.0 cm diameter), with each dish Ϯϲϰ 
then being inoculated with 100 ± 5 Aspergillus conidia. After incubation for 16 h at 37 Ϯϲϱ 
ºC, wells were examined for spore germination using an inverted microscope (Nikon Ϯϲϲ 
Diphot, Japan), and the number of germinated, and non-germinated, spores Ϯϲϳ 
 o
n
 June 20, 2017 by CARDIFF UNIVERSITY
http://aac.asm
.org/
D
ow
nloaded from
 
recorded. MICs in this assay (Table 1) correspond to fluconazole analog Ϯϲϴ 
concentrations resulting in inhibition of spore germination. Ϯϲϵ 
 ϮϳϬ 
In vitro cytotoxicity assays. Two approaches were performed to assess the Ϯϳϭ 
cytotoxicity of the fluconazole analogues. First, using a standard haemolytic assay ϮϳϮ 
[28], erythrocytes from healthy individuals were suspended in phosphate buffered Ϯϳϯ 
saline (PBS) to give a 2 % suspension (v/v). These cells were then incubated with Ϯϳϰ 
various concentrations of each compound for 1 h at 37 °C before being pelleted by Ϯϳϱ 
centrifugation at 3000 x g for 10 min. The percentage haemolysis was then Ϯϳϲ 
calculated from the optical density at 450 nm of the supernatant (Figure 4a). The Ϯϳϳ 
effect of solvent and PBS on erythrocyte viability was also checked. Triton X-100 Ϯϳϴ 
(Sigma Chemicals, USA) was used for complete haemolysis of the erythrocytes. Ϯϳϵ 
In an alternate approach, an MTT-based assay [29] was used to examine the ϮϴϬ 
cytotoxicity of the analogues against A549 (human pulmonary epithelial cells) Ϯϴϭ 
and U87 (primary glioblastoma cells) human cell lines, obtained from National ϮϴϮ 
Centre for Cell Science, Pune, India (Figures 4b and 4c). Briefly, cells were Ϯϴϯ 
cultured in RPMI-1640 medium supplemented with L-glutamine and fetal calf Ϯϴϰ 
serum (10 % v/v), before being harvested at the log phase of confluency and Ϯϴϱ 
re-suspended in RPMI-1640 medium. Samples (2 x 104 cells in 100 µL) were Ϯϴϲ 
seeded into culture plates and allowed to grow overnight at 37 °C under 5 % Ϯϴϳ 
(v/v) CO2. Fluconazole analogues were added at a variety of concentrations Ϯϴϴ 
and the cells were incubated under the same conditions for 24 h. Equivalent Ϯϴϵ 
amounts of solvent, amphotericin B and fluconazole were used as negative ϮϵϬ 
and positive controls. The medium was removed from each well before the Ϯϵϭ 
addition of 50.0 µg of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium ϮϵϮ 
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bromide (MTT) in PBS (100 µL). After incubation for a further period of 4 h at Ϯϵϯ 
37 °C, the MTT solution was removed and the cells were lysed using Ϯϵϰ 
isopropanol-HCl (100.0 µL). The absorption of each well (at 540 nm) was used Ϯϵϱ 
to determine the percentage cytotoxicity in a micro-plate reader (Spectra max Ϯϵϲ 
384 plus, Molecular Devices, USA). Ϯϵϳ 
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Figure Captions ϰϬϭ 
Figure 1. CAL-B catalyzed epoxide ring opening with open chain and cyclic aliphatic ϰϬϮ 
amines. Note that samples of each compound could also be prepared in racemic ϰϬϯ 
form by heating the epoxide and amine at 55 oC in THF (see Supporting ϰϬϰ 
Information). The new stereogenic centre is indicated by an asterisk. ϰϬϱ 
Figure 2. In vitro release of (-)-S-3d from O-hexadecyl- (blue triangles), O-decyl- ϰϬϲ 
(red circles) and O-heptyl-derivatized (grey squares) dextran nanoparticles. ϰϬϳ 
Figure 3. In vitro antifungal activity of (-)-S-3d, amphotericin B and their ϰϬϴ 
dextran NPs. Lane a: Negative control; Lane b: Empty O-alkyl dextran ϰϬϵ 
nanoparticles; Lane c: Amphotericin B; Lane d: Fluconazole; Lane e: (-)-S-3d; ϰϭϬ 
Lane f: O-heptyl nanoparticles containing (-)-S-3d; Lane g: O-decyl ϰϭϭ 
nanoparticles containing (-)-S-3d; Lane h: O-hexadecyl nanoparticles ϰϭϮ 
containing (-)-S-3d; Lanei: O-heptyl nanoparticles containing Amphotericin B; ϰϭϯ 
Lane j: O-decyl nanoparticles containing Amphotericin B; Lane k: O-hexadecyl ϰϭϰ 
nanoparticles containing Amphotericin B.  ϰϭϱ 
Figure 4. In vitro cytotoxicity assays for optically enriched (-)-S-3d and amphotericin ϰϭϲ 
B in both the free form and when encapsulated into dextran nanoparticles. (a) ϰϭϳ 
Haemolytic assay; MTT-based assay using (b) A459 and (c) U87 cell lines. ϰϭϴ 
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Table 1: In vitro activity of selected, optically enriched fluconazole analogues against Aspergillus species.a,b 
 Analogue 
Aspergillus fumigatus Aspergillus niger Aspergillus flavus 
MDA 
(µg/ml) 
DDA 
(µg/disc) 
PSGI 
(µg/ml) 
MDA 
(µg/ml) 
DDA 
(µg/disc) 
PSGI 
(µg/ml) 
MDA 
(µg/ml) 
DDA 
(µg/disc) 
PSGI 
(µg/ml) 
(-)-S-3a 
 
125.0 
(250.0) 
62.50 
(125.0) 
125.0 
(250.0) 
250.0 
(250.0) 
125.0 
(125.0) 
250.0 
(250.0)
250.0 
- 
125.0 
- 
250.0 
- 
(-)-S-3b 
 
250.0 
(250.0) 
62.50 
(125.0) 
250.0 
(250.0) 
500.0 
- 
125.0 
- 
500.0 
- 
- 
- 
- 
- 
- 
- 
(-)-S-3c 
 
62.50 
(125.0) 
31.25 
(31.25) 
62.50 
(125.0) 
62.50 
(500.0) 
 
31.25 
(125.0) 
 
62.50 
(500.0)
500.0 
(1000.0) 
125.0 
(125.0) 
500.0 
(1000.0) 
(-)-S-3d 
 
15.62 
(15.62) 
7.81 
(7.81) 
15.62 
(15.62) 
62.50 
(125.0) 
15.62 
(31.25) 
62.50 
(125.0)
125.0 
(125.0) 
15.62 
(31.25) 
125.0 
(125.0) 
(-)-S-3e 
 
62.50 
(125.0) 
31.25 
(62.50) 
62.50 
(125.0) 
125.0 
(500.0) 
62.50 
(125.0) 
125.0 
(500.0)
500.0 
(500.0) 
125.0 
- 
500.0 
(500.0) 
(-)-S-3i 
 
500.0 
(500.0) 
250.0 
(250.0) 
500.0 
(500.0) 
500.0 
- 
125.0 
- 
500.0 
- 
500.0 
- 
250.0 
- 
500.0 
- 
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(-)-S-5b 
 
62.50 
(125.0) 
31.25 
(62.50) 
62.50 
(125.0) 
125.0 
(500.0) 
62.50 
(125.0) 
125.0 
(500.0)
500.0 
(500.0) 
125.0 
(125.0) 
500.0 
(500.0) 
 
 
Fluconazole 
250.0 125.0 250.0 250.0 125.0 250.0 250.0 125.0 250.0 
Amphotericin B 1.95 0.97 1.95 1.95 0.97 1.95 1.95 0.97 1.95 
 
aValues in parentheses are for the racemic form of the compound. 
b(-) shows no activity within the range of concentrations tested. 
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